Neurol. pro Praxi, 2003; 3: 144-147

Úloha endokanabinoidního systému v projevech postižení nervového systému

prof. MUDr. Alexandra Šulcová CSc
Farmakologický ústav lékařské fakulty Masarykovy univerzity, Brno

Keywords: endokanabinoidní systém, bolest, roztroušená skleróza, epilepsie, neuroprotekce.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šulcová A. Úloha endokanabinoidního systému v projevech postižení nervového systému. Neurol. praxi. 2003;4(3):144-147.

Průkaz specifického farmakologického působení kanabinoidů prostřednictvím receptorů a existence endogenních ligandů těchto receptorů podnítil významně snahy o pochopení jejich fyziologické a patofyziologické úlohy. Podle dosud prokázaných vlivů endogenně se vyskytujících kanabinoidů jsou tyto nazývány retrográdními synaptickými posly s většinou inhibičním působením na řadu známých neurotransmiterových systémů. Podle distribuce receptorů a buněk uvolňujících endokanabinoidy v nervovové síti lze předpokládat, že tento tzv. endokanabinoidní systém může spolupůsobit při vzniku, ale i nápravě projevů postižení nervového systému, a to zejména bolestí, roztroušené sklerózy, spasticity a tremoru, epilepsie a v procesech neurodegenerace i neuroprotekce.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Campbell FA. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic Review. BMJ 2001; 323 (7303): 13-17. Go to original source... Go to PubMed...
    2. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001; 356: 381-408. Go to original source... Go to PubMed...
    3. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25 (4): 743-765. Go to original source... Go to PubMed...
    4. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42 (10): 1266-1272. Go to original source... Go to PubMed...
    5. Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton NY: Haworth Press, 2002.
    6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54 (2): 161-202. Go to original source... Go to PubMed...
    7. Killestein J. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407. Go to original source... Go to PubMed...
    8. Marsden ChA, Šulcová A, Pratt J. Workshop Final Report: Psychopharmacology of cannabinoids and ecstasy. Adiktologie 2002; 1 (Suppl. 1): 7-13.
    9. Martin BR. Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J Pharm Exp Ther 2002; 301: 790-796. Go to original source... Go to PubMed...
    10. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development Expert Opin Inv Drug 2000; 9: (7) 1553-1571. Go to original source... Go to PubMed...
    11. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611. Go to original source... Go to PubMed...
    12. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: (2): 165-174. Go to original source... Go to PubMed...
    13. Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90 (1): 45-60. Go to original source... Go to PubMed...
    14. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-115. Go to original source... Go to PubMed...
    15. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57 (11): 2108-2111. Go to original source... Go to PubMed...
    16. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60 (6): 1303-1314. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.